Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 11
Submit an article Journal homepage
65
Views
17
CrossRef citations to date
0
Altmetric
Review

Nitric oxide-modulating agents for gastrointestinal disorders

Brendan JR Whittle William Harvey Research Institute, Bart’s and The London, Queen Mary’s School of Medicine, Charterhouse Square, London, EC1M 6BQ, UK. [email protected]
Pages 1347-1358 | Published online: 28 Oct 2005

Bibliography

  • TEPPERMAN BL, WHITTLE BJR: Therapeutic implications of the nitric oxide pathway in gastrointestinal diseases. In: Drug Development: Molecular Targets for GI Diseases. Gaginella TS, Guglietta A (Eds), Humana Press, New Jersey, USA (2000):21–60.
  • SHAH V, LYFORD G, GORES G, FARRUGIA G: Nitric oxide in gastrointestinal health and disease. Gastroenterology (2004) 126:903–913.
  • WHITTLE BJR, LAMARQUE D: Interactions of superoxide, nitric oxide and superoxide dismutase in gastrointestinal damage by non-steroidal anti-inflammatory drugs and other agents. In: Therapeutic Application of Superoxide Dismutase and its Mimetics. Salvemini D, Cuzzocrea S (Eds), EurekatilLandes Biosciences, Texas, USA (2005):1–21.
  • KOLIOS G, VALATAS V, WARD SG: Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology (2004) 113:427–437.
  • WHITTLE BJR: Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer anti-inflammatory drugs. Curr. Opia Phannacol. (2004) 4:538–545.
  • DRAZEN JM: COX-2 inhibitors-a lesson in unexpected problems. N Engl. I Med. (2005) 352:1131–1132.
  • ••A discussion of the cardiovascularproblems that have beset the COX-2 Inhibitors.
  • WALLACE JL, DEL SOLDATO P: The therapeutic potential of NO-NSAIDs. Fundain. Clin. Phannacol. (2003) 17:11–20.
  • ••A thorough review of the pharmacologyand research underlying the development of NO-NSAIDs by two of the originators.
  • LANAS A, BAJADOR E, SERRANO P et al: Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs,and the risk of upper gastrointestinal bleeding. N Engl. J. Med. (2000) 343:834–839.
  • FIORUCCI S, DEL SOLDATO P: NO-aspirin: mechanism of action and gastrointestinal safety. Dig. Liver Dis. (2003) 35\(Suppl. 2):59–519.
  • RIGAS B, KASHFI K: Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol. Med. (2004) 10:324–330.
  • THATCHER GR, NICOLESCU AC, BENNETT BM, TOADER V: Nitrates and NO release: contemporary aspects in biological and medicinal chemistry. Free Radic. Biol. Med. (2004) 37:1122–1143.
  • ••A detailed analysis of the chemical andbiochemical aspects of NO and NO donors.
  • CARINI M, ALDINI G, ORIOLI M, PICCOLI A, ROSSONI G, FACINO R: Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat. Life Li. (2004) 74:3291–3305.
  • CARINI M, ALDINI G, ORIOLI M, PICCOLI A, TOCCHETTI P, RM: Chemiluminescence and -MS/MS analyses for the study of nitric oxide release and distribution following oral administration of nitroaspirin (NCX 4016) in healthy volunteers. J. Phann.. Anal. (2004) 35:277–287.
  • •Study of the human pharmacokinetic profile of NO-aspirin.
  • ZACHAROWSKI P, BREESE E, WOOD E et al: NSAIDs increase GM-CSF release by human synoviocytes: comparison with nitric oxide-donating derivatives. Eur. Phannacol (2005) 508:7–13.
  • ZACHAROWSKI P, ZACHAROWSKI K, DONNELLAN C et al: The effects and metabolic fate of nitroflurbiprofen in healthy volunteers. Clin. Phannacol Ther. (2004) 76:350–358.
  • FAGERHOLM U, BREUER 0, SWEDMARK S, HOOGSTRAATE J: Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.. Phannacol (2005) 57:587–597.
  • HAWKEY CJ, JONES JI, CT et al: Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut (2003) 52:1537–1542.
  • •The first clinical evaluation of NO-naproxen.
  • BERNDT G, GROSSER N, HOOGSTRAATE J, SCHRODER H: A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate. Eur. Phann. Li. (2004) 21:331–335.
  • •Studies on the similarities of GTN and NO-naproxen as NO-donating compounds.
  • ADDING LC, AGVALD P, ANDERSSON LI, JONZON B, HOOGSTRAATE J, GUSTAFSSON LE: Direct gas measurements indicate that the novel cyclooxygenase inhibitor AZD3582 is an effective nitric oxide donor in vivo. Br. J. Pharmacol (2005) 145:679–687.
  • FIORUCCI S, SANTUCCI L, GRESELE P, FACCINO RM, DEL SOLDATO P, MORELLI A: Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology (2003) 124:600–607.
  • FIORUCCI S, MENCARELLI A, MENEGUZZI A et al: Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. J. Ain. Coll Cardiol (2004) 44:635–641.
  • •An interesting evaluation of NO-aspirin in the clinic.
  • HOOGSTRAATE J, ANDERSSON LI, BERGE OG, JONZON B, OJTEG G: COX-inhibiting nitric oxide donators (CINODs) - a new paradigm in the treatment of pain and inflammation. InlIaminopharinacology (2003) 4:423–428.
  • JONZON B, BJARNASON I, HAWKEY C et al: The CINOD, AZD3582, exhibits an improved gastrointestinal safety profile compared with naproxen in healthy volunteers. InlIaminopharinacology (2003) 11:437–444.
  • LOHMANDER LS, McKEITH D, SVENSSON 0 et al.: STAR Multinational Study Group. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann. Rheum. Dis. (2005) 64:449–456.
  • ••An important Phase II evaluation of theefficacy and side-effect profile of NO-naproxen.
  • VELAZQUEZ C, PRAVEEN RAO PN, KNAUS EE: Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies. J. Med. Chem. (2005) 48:4061–4067.
  • KHANAPURE SP, GARVEY DS, YOUNG DV et al: Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective. J. Med. Chem. (2003) 46:5484–5504.
  • RANATUNGE RR, GARVEY DS, JANERO DR et al: Synthesis and selective cyclooxygenase-2 (COX-2) inhibitory activity of a series of novel bicyclic pyrazoles. Bioorg. Med. Chem. (2004) 12:1357–1366.
  • RANATUNGE RR, AUGUSTYNIAK M, BANDARAGE UK et al: Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles. J. Med. Chem. (2004) 47:2180–2193.
  • RAJA SG, NAYAK SH: Sildenafil: emerging cardiovascular indications. Ann. Thome. Surg. (2004) 78:1496–1506.
  • EHERER AJ, SCHWETZ I, HF et al: Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut (2002) 50:758–764.
  • LEE JI, PARK H, KIM JH, LEE SI, CONKLIN JL: The effect of sildenafil on oesophageal motor function in healthy subjects and patients with nutcracker oesophagus. Neurogastroentero. Moth. (2003) 15:617–623.
  • SARNELLI G, SIFRIM D, JANSSENS J, TACK J: Influence of sildenafil on gastric sensorimotor function in humans. Am. J. Physiol Castrointest. Liver Physiol (2004) 287:G988–G992.
  • MADSEN JL, SONDERGAARD SB, FUGLSANG S, RUMESSEN JJ, GRAFF J: Effect of sildenafil on gastric emptying and postprandial frequency of antral contractions in healthy humans.. Castroenterol (2004) 39:629–363.
  • DISHY V, COHEN POUR M, L et al: The effect of sildenafil on gastric emptying in patients with end-stage renal failure and symptoms of gastroparesis. Clin. Pharmacol Ther. (2004) 76:281–286.
  • COLESKI R, GONLACHANVIT S, OWYANG C, HASLER WL: Selective reversal of hyperglycemia-evoked gastric myoelectric dysrhythmias by nitrergic stimulation in healthy humans. Pharmacol Exp. Ther. (2005) 312:103–111.
  • LINDSEY I, JONES OM, C, MORTENSEN NJ: Chronic anal fissure. BE I Surg. (2004) 91:270–279.
  • SCHOLEFIELD JH, BOCK JU, MARLA B et al.: A dose finding study with 0.1%, 0.2%, and 0.4% glyceryl trinitrate ointment in patients with chronic anal fissures. Cut (2003) 52:264–269.
  • ••A report on the efficacy of a topical NO in this painful and debilitating disease.
  • PARELLADA C: Randomized, prospective trial comparing 0.2 percent isosorbide dinitrate ointment with sphincterotomy in treatment of chronic anal fissure: a two-year follow-up. Dis. Colon Rectum (2004) 47:437–443.
  • TORRABADELLA L, SALGADO G, BURNS RW, BERMAN IR: Manometric study of topical sildenafil (Viagra) in patients with chronic anal fissure: sildenafil reduces anal resting tone.. Colon Rectum (2004) 47:733–738.
  • GOSSELINK MP, DARBY M, ZIMMERMAN DD, GRUSS HJ, SCHOUTEN WR: Treatment of chronic anal fissure by application of L-arginine gel: a Phase II study in 15 patients. Dis. Colon Rectum (2005) 48:832–837.
  • CROSS RK, WILSON KT: Nitric oxide ininflammatory bowel disease.. Bowe] Dis. (2003) 9:179–189.
  • ANDRESEN L, JORGENSEN VL, PERNER A, HANSEN A, EUGEN-OLSEN J, RASK-MADSEN J: Activation of nuclear factor KB in colonic mucosa from patients with collagenous and ulcerative colitis. Gut (2005) 54:503–509.
  • KRISTJANSSON G, HOGMAN M, VENGE P, HALLGREN R: Gut mucosal granulocyte activation precedes nitric oxide production: studies in coeliac patients challenged with gluten and corn. Gut (2005) 54:769–774.
  • LAMARQUE D, NHIEU JT, BREBAN M et al.: Lymphocytic infiltration and expression of inducible nitric oxide synthase in human duodenal and colonic mucosa is a characteristic feature of ankylosing spondylitis. j Rheumatol (2003) 30:2428–2436.
  • MENCHEN L, COLON AL, JL et al:Activity of inducible and neuronal nitric oxide synthases in colonic mucosa predicts progression of ulcerative colitis. Am. J. Castroenterol (2004) 99:1756–1764.
  • POON BY, RAHARJO E, PATEL KD, TAVENER S, KUBES P: Complexity of inducible nitric oxide synthase: cellular determines benefit versus toxicity. Circulation (2003) 108:1107–1112.
  • VALLANCE BA, DIJKSTRA G, QIU B et al: Relative contributions of NOS isoforms during experimental colitis: endothelial-derived NOS maintains mucosal integrity. Am. I Physiol Gastrointest. Liver Physiol (2004) 287:G865–874.
  • BECK PL, XAVIER R, WONG J et al.: Paradoxical roles of different nitric oxide synthase isoforms in colonic injury. Am. Physiol Gastrointest. Liver Physiol (2004) 286:G137–G147.
  • KANKURI E, VAALI K, KNOWLES RG et al.: Suppression of acute experimental colitis by a highly selective inducible nitric-oxide synthase inhibitor, N- [3-(aminomethyl)benzyll acetamidine. Pharmacol Exp. Ther. (2001) 298:1128–1132.
  • MEN CHEN LA, COLON AL, MORO MA et al: N- (3-(aminomethyObenzyl)acetamidine, an inducible nitric oxide synthase inhibitor, decreases colonic inflammation induced by trinitrobenzene sulphonic acid in rats. Life Sci. (2001) 69:479–491.
  • DI PAOLA R, MAZZON E, PATEL NS et al. Beneficial effects of GW274150 treatment on the development of experimental colitis induced by dinitrobenzene sulfonic acid.. Pharmacol (2005) 507:281–289.
  • KANKURI E, HAMALAINEN M, HUKKANEN M et al.: Suppression of pro-inflammatory cytokine release by selective inhibition of inducible nitric oxide synthase in mucosal explants from patients with ulcerative colitis. Scand. Gastroenterol (2003) 38:186–192.
  • GREEN CL, HO W, SHARKEY KA, McKAY DM: Dextran sodium sulfate-induced colitis reveals nicotinic modulation of ion transport via iNOS-derived NO. Am. I Physiol Gastrointest. Liver. Physiol (2004) 287:G706–G714.
  • KISS J, LAMARQUE D, MORAN AP et al.: Helicobacter pylori lipopolysaccharide-provoked injury to rat gastroduodenal microvasculature involves inducible nitric oxide synthase. Eur. Pharmacol (2001) 420:175–179.
  • NAITO Y, TAKAGI T, ICHIKAWA H et al. A novel potent inhibitor of inducible nitric oxide inhibitor, ONO-1714, reduces ischemia-reperfusion injury in. Nitric Oxide (2004) 10:170–177.
  • TINKER AC, BEATON HG, BOUGHTON-SMITH N et al: 1,2-Dihydro-4-quinazolinamines: potent, highly selective inhibitors of inducible nitric oxide synthase which show antiinflammatory activity in vivo.. Chem. (2003) 46:913–916.
  • SANDSTROM P, BROOKE-SMITH ME, THOMAS AC et al.: Highly selective inhibition of inducible nitric oxide synthase ameliorates experimental acute pancreatitis. Pancreas (2005) 30:e10–e15.
  • CONNOLLY S, ABERG A, ARVAI A et al.: 2-Aminopyridines as highly selective inducible nitric oxide synthase inhibitors. Differential binding modes dependent on nitrogen substitution. J. Med. Chem. (2004) 47:3320–3323.
  • JACKSON SA, SAHNI S, LEE L et al: Design, synthesis and characterization of a novel class of coumarin-based inhibitors of inducible nitric oxide synthase.. Med. Chem. (2005) 13:2723–2739.
  • GUTHIKONDA RN, SHAH SK, PACHOLOK SG et al. Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inhibitors of inducible nitric oxide synthase. Bioorg. Med. Chem. Lett. (2005) 15:1997–2001.
  • PACHER P, SCHULZ R, LIAUDET L, SZABO C: Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci. (2005) 26:302–310.
  • ••A recent review of the aspects of NObiochemistry underlying the cytotoxicity.
  • MUSCOLI C, CUZZOCREA S, DP et al: On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Br. J. Pharmacol (2003) 140:445–460.
  • ••A detailed pharmacological appraisal of theuse of superoxide scavengers to reduce NO toxicity.
  • WHITTLE BJR: Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam. Clin. Pharmacol (2003) 17:301–313.
  • LAINE L, CONNORS LG, REICIN A eta].: Serious lower gastrointestinal clinical events with non selective NSAID or coxib use. Gastroenterology (2003) 124:288–292.
  • EVANS SM, WHITTLE BJR: Role of bacteria and inducible nitric oxide synthase activity in the systemic inflammatory microvascular response provoked by indomethacin in the rat. Eur. I Pharmacol (2003) 461:63–71.
  • WHITTLE BJR: Mechanisms underlyingintestinal injury induced by anti-inflammatory COX inhibitors.. I Pharmacol (2004) 500:427–439.
  • SUGIMOTO K, HANAI H, TOZAWA K et al: Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology (2002) 123:1912–1922.
  • JIAN YT, MAI GF, WANG JD, ZHANG YL, LUO RC, FANG YX: Preventive and therapeutic effects of NF-KB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World I Gastroenterol (2005) 11:1747–1752.
  • SANCHEZ DE MEDINA F, VERA B, GALVEZ J, ZARZUELO A: Effect of quercitrin on the early stages of hapten induced colonic inflammation in the rat. Life Sci. (2002) 70:3097–3108.
  • CAMUESCO D, COMALADA M, RODRIGUEZ-CABEZAS ME eta].: The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br. I Pharmacol (2004) 143:908–918.
  • COMALADA M, CAMUESCO D, SIERRA S et al.: In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-KB pathway. Eur. I Immunol (2005) 35:584–592.
  • KWON KH, MURAKAMI A, T, OHIGASHI H: Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulfate sodium-induced experimental colitis in mice: attenuation of pro-inflammatory gene expression. Biochem. Pharmacol (2005) 69:395–406.
  • HIPPISLEY-COX J, COUPLAND C: Riskof myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br. Med. J. (2005) 330:1366.
  • •A recent and somewhat controversial report on the cardiovascular toxicity of the standard NSAIDs.
  • McCOLL KEL: When saliva meets acid: chemical warfare at the oesophagogastric junction. Gut (2005) 54:1–3.
  • KLEINJANS J, DE KOK T, ENGELS L: Risk assessment of endogenous formation of carcinogenic N-nitroso compounds in response to intake of NO-aspirin. Gastroenterology (2004) 127:1018–1019.
  • LUNDBERG JO, WEITZBERG E, COLE JA, BENJAMIN N: Nitrate, bacteria and human health. Nat. Rev Microbial. (2004) 2:593–602.
  • BJORNE H H, PETERSSON J, PHILLIPSON M, WEITZBERG E, HOLM L, LUNDBERG JO: Nitrite in saliva increases gastric mucosal blood flow and mucus thickness. .1 Clin. Invest. (2004) 113:106–114.
  • WALLACE JL: Nitric oxide-releasing mesalamine: potential utility for treatment of inflammatory bowel disease.. Liver Dis. (2003) 35\(Suppl. 2):S35–S40.
  • WALLACE J, MENCARELLI A, FARNETI S, MORELLI A, FIORUCCI S: Different sensitivity of lamina propria T-cell subsets to nitric oxide-induced apoptosis explains immunomodulatory activity of a nitric oxide-releasing derivative of mesalamine in rodent colitis. Gastroenterology (2005) 128:1243–1257.
  • PAUL-CLARK MJ, ROVIEZZO F, FLOWER RJ et al.: Glucocorticoid receptor nitration leads to enhanced anti- effects of novel steroid ligands. Immunol. (2003) 171:3245–3252.
  • TURESIN F, DEL SOLDATO P, WALLACE JL: Enhanced anti-inflammatory potency of a nitric oxide-releasing prednisolone derivative in the rat. Br. J. Pharmacol. (2003) 139:966–972.
  • BARALDI PG, ROMAGNOLI R, DEL CARMEN NUNEZ M et al: Synthesis of nitro esters of prednisolone, new compounds combining pharmacological properties of both glucocorticoids and nitric oxide. [Med. Chem. (2004) 47:711–719.
  • WALLACE JL, RIZZO G, CIRINO G, DEL SOLDATO P, FIORUCCI S: Enhanced anti-inflammatory potency of a nitric oxide-releasing derivative of flunisolide: role of nuclear factor-KB. Pharmacol. Exp. Ther. (2004) 310:1096–1102.
  • HULEDAL G, JONZON B, M et al.: Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. Clin. Pharmacol. Ther. (2005) 77:437–450.
  • •The first clinical study to focus on the renal effects of NO-naproxen.
  • BRYAN NS, RASSAF T, MALONEY RE et al.: Cellular targets and mechanisms of nitros(yOation: an insight into their nature kinetics in vivo. Proc. Nati Acad. Li. USA (2004) 101:4308–4313.
  • ••A forward looking review on novelsignalling pathways for NO that may yield new targets.
  • MOLLACE V, MUSCOLI C, MASINI E, CUZZOCREA S, SALVEMINI D: Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol. Rev (2005) 57:217–252.
  • ••A comprehensive recent review on theinteraction of the NO system with other key mediators.

Websites

  • http://www.eular.org/.cfm?framePage=/eular2004.cfm A Phase II study of the efficacy and safety of AZD3582, a CINOD, in subjects with osteoarthritris of the knee. EULAR 2004 Conference Abstract 0P0016.
  • http://www.nicox.com/pages/press.asp NicOx Press Release on 27/01/04.
  • http://www.nitromed.com/09_30_04.asp NitroMed Press Release on 30/09/04.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.